USP28

Ubiquitin carboxyl-terminal hydrolase 28 · Q96RU2 · USP28 on Sugi Atlas →

10,319 patent compounds predicted against USP28, 5,371 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1259325 SCHEMBL1259325 0.66 13/20
SCHEMBL1625019 SCHEMBL1625019 0.64 13/20
SCHEMBL2221108 SCHEMBL2221108 0.56 13/20
SCHEMBL1625829 SCHEMBL1625829 0.52 13/20
SCHEMBL1624570 SCHEMBL1624570 0.51 13/20
SCHEMBL1624585 SCHEMBL1624585 0.50 13/20
SCHEMBL2223513 SCHEMBL2223513 0.55 12/20
SCHEMBL2262561 SCHEMBL2262561 0.52 11/20
SCHEMBL2222068 SCHEMBL2222068 0.49 11/20
Vismodegib Vismodegib (SCHEMBL302587) 1.00 9/20
Vismodegib Vismodegib (SCHEMBL1017957) 0.98 9/20
SCHEMBL1258699 SCHEMBL1258699 0.82 9/20
SCHEMBL1990768 SCHEMBL1990768 0.48 9/20
SCHEMBL1014723 SCHEMBL1014723 0.83 8/20
SCHEMBL1019227 SCHEMBL1019227 0.83 8/20
SCHEMBL1258906 SCHEMBL1258906 0.83 8/20
SCHEMBL1021007 SCHEMBL1021007 0.74 8/20
SCHEMBL1259359 SCHEMBL1259359 0.71 8/20
SCHEMBL1457879 SCHEMBL1457879 0.49 8/20
SCHEMBL1016538 SCHEMBL1016538 0.85 7/20

Clinical trials — most relevant to USP28 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Testing the Safety of CB-5339 in Patients With Cancer PHASE1WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness nanRECRUITING
A Natural History Study of Angelman Syndrome nanRECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP28 binder may also engage these)

ProteinNameSimilarity
Q5I043 1.000 Q5I043 →
D3ZJ96 1.000 D3ZJ96 →
P57080 0.997 P57080 →
Q5ZID5 0.995 Q5ZID5 →
Q9LYZ7 0.992 Q9LYZ7 →
Q92562 0.992 Q92562 →
Q86UV5 0.992 Q86UV5 →
Q6ZPS6 0.991 Q6ZPS6 →
Q5ICL9 0.991 Q5ICL9 →
Q12242 0.991 Q12242 →
Q9SUG7 0.991 Q9SUG7 →
A8E7C5 0.991 A8E7C5 →
Q9FY74 0.991 Q9FY74 →
Q6DDJ5 0.991 Q6DDJ5 →
Q9Y2H2 0.991 Q9Y2H2 →
Q94C95 0.990 Q94C95 →
Q6Q4D0 0.990 Q6Q4D0 →
Q6GM53 0.990 Q6GM53 →
P93002 0.990 P93002 →
B2GUY1 0.990 B2GUY1 →
Q3V0C5 0.990 Q3V0C5 →
F4IGA5 0.990 F4IGA5 →
Q811U4 0.990 Q811U4 →
Q7Z3E5 0.990 Q7Z3E5 →
Q1L8G6 0.990 Q1L8G6 →
Q80U87 0.990 Q80U87 →
Q08AX9 0.990 Q08AX9 →
Q9M086 0.990 Q9M086 →
P93042 0.989 P93042 →
Q5JCS6 0.989 Q5JCS6 →